Business

Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences

articleTwist Bioscience CorporationAugust 19, 20253/company/twist-bioscience-corp/news/twist-bioscience-launches-oncology-dna-cgp-panel-advance-precision-medicine
Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution

About this update from Twist Bioscience Corporation

[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nTwist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research.\n\n\n“We designed this panel to break the status quo in genomic profiling by offering laboratories a powerful alternative to locked, one-size-fits-all solutions,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “With our customizable content, flexible workflow, and compatibility with multiple sequencing platforms, Twist’s Oncology DNA CGP Panel puts scientific control back in the hands of researchers and clinicians, particularly for those who need a more cost-effective solution compared to existing CGP products or a more efficient option than smaller panels.”\n\n\nThe Twist Oncology DNA CGP Panel was designed to serve a wide range of research groups including regional clinical labs, academic medical centers, and biopharma partners. The panel composition incorporates clinical research and includes a comprehensive and updated biomarker list covering 562 genes that incorporate all major tumor types. The panel’s coverage spans genomic alterations and genomic signatures and can detect base substitutions, insertions and deletions (indels), copy number variations (CNVs), gene rearrangements as well as measure tumor mutational burden (TMB) and microsatellite instability (MSI). This is paired with Twist high quality and easy-to-use library preparation and target enrichment workflows. Twist is collaborating with several analytics companies to provide a complete solution from sequencing to analysis.\n\n\nAbout Twist Bioscience Corporation\n\n\nAt Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely po...

More updates from Twist Bioscience Corporation